From GlobeNewswire: 2025-02-20 07:10:00

Telix Pharmaceuticals Limited reported financial results for 2024, with total revenue reaching $783.2 million, a 56% increase from the previous year. The company also saw a second year of profitable growth, invested in R&D, and expanded its global supply chain and product delivery infrastructure. Adjusted EBITDA was $99.3 million, up by 70%.

In 2024, Telix achieved key milestones such as preparing for the launch of three new products, expanding prostate cancer therapy trials, delivering clinical proof-of-concept for a prostate cancer treatment, and expanding global delivery infrastructure through acquisitions and facility expansions. The company is focused on precision medicine, late-stage therapeutics, and pipeline development.

Group CEO, Dr. Christian Behrenbruch, highlighted Telix’s strong financial growth in 2024 and emphasized the company’s focus on international business expansion, upcoming product launches, and infrastructure development to improve patient access. Telix is optimistic about significant growth and evolution in 2025.

Telix provided revenue guidance for FY2025 of $1.18 billion to $1.23 billion, including revenue from existing products and acquisitions. The company also expects increased R&D investment compared to 2024. An investor webcast will be held on February 21, 2025.

Telix Pharmaceuticals Limited is a biopharmaceutical company specializing in therapeutic and diagnostic radiopharmaceuticals. Headquartered in Melbourne, Australia, the company operates globally and is listed on the ASX and Nasdaq. Telix is focused on addressing unmet medical needs in oncology and rare diseases through its product portfolio. Visit their website for more information.



Read more at GlobeNewswire:: Telix 2024 Full Year Results: Record Financial Performance